Helicobacter pylori is a major human pathogen associated with significant morbidity. The treatment oriented by the antibiogram or PCR (Polymerase Chain Reaction) should be privileged in children. However, the optimal treatment for the eradication of pediatric H. pylori infection is still not established. No French consensus conference on the management of H. pylori infection in children taking into account the epidemiological data available for this infection has been published. The description of diagnostic and therapeutic management procedures has not yet been specifically described according to the country of birth of children. The main objective is to collect data enabling the establishment of a French observatory of Helicobacter pylori in children in order to provide a national database.
Study Type
OBSERVATIONAL
Enrollment
1,201
The following data will be collected by the physician : sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control.
Lille Catholic University
Lille, France
Diagnosis of H. pylori infection
Child with confirmed H. pylori infection by direct diagnostic methods (Histology, Bacterial culture, PCR) on perendoscopic gastric biopsies
Time frame: at inclusion
Age
Time frame: at inclusion
Sex
Time frame: at inclusion
Country of birth
Time frame: at inclusion
Clinical symptoms
Time frame: at inclusion, 3 and 6 months
Microbiological diagnosis
Time frame: at inclusion, 3 and 6 months
Endoscopic diagnosis
Time frame: at inclusion, 3 and 6 months
Rates of bacterial resistance profiles
Time frame: at inclusion, at 3 and 6 months
antibiotic therapy
Time frame: at inclusion, 3 and 6 months
Bacterial eradication rates
Time frame: 3 and 6 months
Side effects and tolerance of first and second line treatments
Time frame: 3 and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.